Dimerix Ltd Forms Strategic Partnership with FUSO Pharmaceutical Industries for Development of DMX-200 in Japan
Dimerix Ltd Forms Strategic Partnership with FUSO Pharmaceutical Industries for Development of DMX-200 in Japan
01/07/25, 12:51 AM
Location
melbourneMoney
¥910 million
Industry
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Type
partnership
Dimerix Ltd has surged by 31% as a result of a significant announcement of a partnership with FUSO Pharmaceutical Industries in Japan. This exclusive collaboration focuses on the development and commercialization of DMX-200, a promising drug candidate targeting FSGS, a kidney disease. FUSO will lead the efforts in Japan and provide financial support for the development, regulatory, and commercial initiatives.
Company Info
Location
melbourne, victoria, australia
Additional Info
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets.
Dimerix is currently developing its proprietary product, DMX-200, for kidney diseases and for respiratory complications associated with COVID-19.
Dimerix has three Phase 3 clinical programs with near term value propositions
1) Global Phase 3 REMAP-CAP study in at least 200 hospitalised COVID-19 patients with respiratory pneumonia in Europe and UK
2) Multi-national Phase 3 CLARITY 2.0 study in at least 600 COVID-19 patients with respiratory complications in India
3) Global Phase 3 study in Focal Segmental Glomerulosclerosis (FSGS) patients, which is a rare kidney disease, following positive Phase 2 data in 2020 and for which Dimerix has been granted Orphan Drug Designation by the FDA and EMA
Dimerix also has longer term programs in Diabetic Kidney Disease and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).